MENQUADFI SOLUTION FOR INJECTION

Therapeutic indications

MenQuadfi is indicated for active immunisation of individuals from the age of 12 months and older against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y.

The use of this vaccine should be in accordance with available official recommendations.

Contraindications

Hypersensitivity to the active substances or to any of the excipients listed in section List of excipients or after previous administration of the vaccine or a vaccine containing the same components – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information.

Posology and method of administration

Posology

Primary vaccination:

• Individuals 12 months of age and older: One single dose (0.5 mL).

Booster vaccination:

• A single 0.5 mL dose of MenQuadfi may be used to boost subjects who have previously received a meningococcal vaccine containing the same serogroups (see section Pharmacodynamic properties – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
• Long-term antibody persistence data following vaccination with MenQuadfi are available up to 7 years after vaccination (see sections Special warnings and precautions for use and Pharmacodynamic properties – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
• There are no data available to indicate the need for or timing of a booster dose of MenQuadfi (see section Pharmacodynamic properties – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).

Other paediatric population

The safety and immunogenicity of MenQuadfi in individuals under 12 months of age have not yet been established.

Method of administration

For intramuscular injection only, preferably in the deltoid region or anterolateral thigh depending on the recipient's age and muscle mass.

For instructions on handling of the vaccine before administration, see section Special precautions for disposal and other handling – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information.